HDFC MNC Fund vs HDFC Pharma and Healthcare Fund
Direct Plan, Growth option · Data as on 30-10-2026
HDFC MNC Fund is a Thematic fund and HDFC Pharma and Healthcare Fund is a Thematic fund. In the 3 years to 30-10-2026, HDFC MNC Fund (Direct) returned 6.2% a year and HDFC Pharma and Healthcare Fund (Direct) returned 30.5% a year. HDFC MNC Fund charges 1.86% a year and HDFC Pharma and Healthcare Fund 1.05% (Direct plans). Their portfolios overlap 19.7%: they hold 12 of the same securities.
HDFC Pharma and Healthcare Fund
Thematic
- 3 year return
- 30.5%
- Expense ratio
- 1.05%
- NAV
- ₹21.95
Which is better, HDFC MNC or HDFC Pharma and Healthcare? Key differences
It depends on what you want from the fund. These are the differences in numbers, from the data on this page.
- HDFC Pharma and Healthcare returned more over 3 years: 30.5% a year against 6.2%.
- HDFC Pharma and Healthcare returned more over 1 year: 23.1% against −3.7%.
- HDFC Pharma and Healthcare costs less: 1.05% a year against 1.86% (Direct plans).
- HDFC MNC swung less over 3 years: a standard deviation of 13.1% a year against 14.1%.
- HDFC Pharma and Healthcare fell less in its worst fall since 04-10-2023: −14.9% against −24.5%.
- HDFC MNC holds more in large companies: 51.4% of the fund in large caps against 29.2%.
- HDFC Pharma and Healthcare is the larger fund: ₹3,501 Cr against ₹534 Cr.
- Their portfolios overlap 19.7%: 12 of the same holdings.
Past returns do not promise future returns. This page is information, not investment advice.
Key facts
From each fund's scheme summary document and AMFI
| Fact | HDFC MNC Fund | HDFC Pharma and Healthcare Fund |
|---|---|---|
| Fund house | HDFC Mutual Fund | HDFC Mutual Fund |
| Category | Thematic | Thematic |
| AUM | ₹534 Cr (30-09-2026) | ₹3,501 Cr (30-09-2026) |
| NAV | ₹13.66 (Direct) | ₹21.95 (Direct) |
| Expense ratio (Direct) | 1.86% | 1.05% |
| Expense ratio (Regular) | 2.89% | 2.13% |
| Riskometer | Very High | Very High |
| Benchmark | Nifty MNC TRI | BSE Healthcare TRI |
| Launch date | 09-03-2023 | 04-10-2023 |
| Minimum investment | ₹100 | ₹100 |
| Lock in | None | None |
| Fund managers | Amar Kalkundrikar, Gopal Agrawal, Bhagyesh Kagalkar | Nikhil Mathur, Gopal Agrawal, Bhagyesh Kagalkar |
| Exit load | - In respect of each purchase / switch-in of Units, an Exit Load of 1.00% is payable if Units are redeemed/ switched-out within 1 year from the date of allotment. - No Exit Load is payable if Units are redeemed / switched-out after 1 year from the date of allotment. | In respect of each purchase/switch-in of units, an Exit load of 1% is payable if units are redeemed /switched-out within 30 days from the date of allotment. No Exit Load is payable if units are redeemed / switched out after 30 days from the date of allotment. |
HDFC MNC vs HDFC Pharma and Healthcare: Returns Comparison
Returns as on 30-10-2026. Up to one year they are absolute returns. Longer periods are a rate per year.
| Fund | 1M | 3M | 6M | 1Y | 3Y | 5Y | 10Y |
|---|---|---|---|---|---|---|---|
| HDFC MNC Fund (Direct) | −3.30% | −4.94% | −0.12% | −3.66% | +6.19% | -- | -- |
| HDFC Pharma and Healthcare Fund (Direct) | +0.04% | +0.83% | +16.68% | +23.12% | +30.53% | -- | -- |
| Thematic average | −2.09% | −4.52% | +0.86% | −1.22% | +13.76% | -- | -- |
Category average: the average of the 235 Thematic funds, same plan type.
HDFC MNC vs HDFC Pharma and Healthcare: Year-wise Returns
| Year | MNCHDFC MNC | Pharma and HealthcareHDFC Pharma and Healthcare |
|---|---|---|
| 2026to date | −2.49% | +23.99% |
| 2025 | +0.58% | +2.42% |
| 2024 | +9.82% | +52.22% |
HDFC MNC vs HDFC Pharma and Healthcare: Rolling Returns
Every holding period of both funds, against Nifty MNC TRI, the benchmark of HDFC MNC Fund
Rolling returns
Every 1-year holding period, 510 of them, one for each trading day from 04-10-2024 to 30-10-2026: the yearly return (CAGR) of each, plotted on the day it ended. One lucky or unlucky start day cannot flatter or hide a fund.
HDFC MNC Fund (Direct)
HDFC Pharma and Healthcare Fund (Direct)
Nifty MNC TRI
to
Dec 2024Apr 2024
to
Apr 2025Aug 2024
to
Aug 2025Dec 2024
to
Dec 2025May 2025
to
May 2026Aug 2025
to
Aug 2026
How the periods spread
| Fund | Below 0% | 0-5% | 5-10% | 10-15% | 15-20% | 20-25% | Above 25% | Mean | Median | Lowest | Highest | Beat benchmark |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HDFC MNC | 43.5 | 23.9 | 16.3 | 5.1 | 5.3 | 2.2 | 3.7 | 2.7% | 1.2% | −11.5% | 33.3% | 1% |
| HDFC Pharma and Healthcare | 0.0 | 4.3 | 15.7 | 9.2 | 10.0 | 17.6 | 43.1 | 24.6% | 22.7% | 1.7% | 67.3% | 82% |
| Nifty MNC TRI | 24.9 | 15.9 | 10.2 | 17.1 | 14.7 | 6.9 | 10.4 | 10.0% | 9.8% | −7.7% | 46.5% | -- |
The table shows the % of periods in each return band; a darker cell holds more of them. Lumpsum: the yearly rate (CAGR) from a period's first NAV to its last. SIP: the XIRR of the monthly instalments. The benchmark is Nifty MNC TRI, over the same periods. "Beat benchmark" counts the periods in which the fund did better. Every fund is measured over the days all of them have, from 04-10-2023. Past returns do not promise future returns.
HDFC MNC vs HDFC Pharma and Healthcare: SIP and Lumpsum Returns
What the same monthly or one-time investment would be worth in each fund today, from their own NAV history
Growth of an investment
₹10,000 on the first trading day of every month, from 03-10-2023 to 30-10-2026: 37 instalments, ₹3,70,000 in all.
| Investment | Invested | Value now | Gain | Return a year |
|---|---|---|---|---|
| HDFC MNCHDFC MNC Fund (Direct) | ₹3,70,000 | ₹3,74,818 | ₹4,818 | 0.8% |
| HDFC Pharma and HealthcareHDFC Pharma and Healthcare Fund (Direct) | ₹3,70,000 | ₹5,26,145 | ₹1,56,145 | 23.6% |
HDFC MNCHDFC MNC Fund (Direct)
HDFC Pharma and HealthcareHDFC Pharma and Healthcare Fund (Direct)
Amount invested
From each plan's published NAV (Growth option), over the same days. Return a year: XIRR for a SIP, CAGR for a lumpsum, shown for a year or more. It does not include exit load, stamp duty or tax. Past returns do not promise future returns.
HDFC MNC vs HDFC Pharma and Healthcare: Risk and Drawdowns
How much each fund swings, and the worst fall over the same days
Risk and return
| Measure | HDFC MNC Fund (Direct) | HDFC Pharma and Healthcare Fund (Direct) |
|---|---|---|
| Return (CAGR) | −3.66% | +23.12% |
| Standard deviation | 14.18% | 13.67% |
| Sharpe ratio | -0.63 | 1.31 |
| Sortino ratio | -0.82 | 1.93 |
| Maximum drawdown | −14.2% (30-03-2026) | −9.8% (23-10-2026) |
| Beta | 0.87 | 0.95 |
| Alpha | +0.04% | +11.09% |
From daily NAVs, 30-10-2025 to 30-10-2026. Standard deviation: how much the daily value swings, scaled to a year. Sharpe: return above the risk-free rate (NSE's overnight rate index) per unit of swing. Sortino: the same, counting only the falls. Beta and alpha compare each fund with its own benchmark's TRI.
| Measure | HDFC MNC Fund (Direct) | HDFC Pharma and Healthcare Fund (Direct) |
|---|---|---|
| Return (CAGR) | +6.19% | +30.53% |
| Standard deviation | 13.13% | 14.09% |
| Sharpe ratio | 0.01 | 1.74 |
| Sortino ratio | 0.02 | 2.49 |
| Maximum drawdown | −24.5% (28-02-2025) | −14.9% (28-02-2025) |
| Beta | 0.88 | 0.96 |
| Alpha | −4.01% | +8.23% |
From daily NAVs, 30-10-2023 to 30-10-2026. Standard deviation: how much the daily value swings, scaled to a year. Sharpe: return above the risk-free rate (NSE's overnight rate index) per unit of swing. Sortino: the same, counting only the falls. Beta and alpha compare each fund with its own benchmark's TRI.
| Measure | HDFC MNC Fund (Direct) | HDFC Pharma and Healthcare Fund (Direct) |
|---|---|---|
| Return (CAGR) | +8.90% | +29.32% |
| Standard deviation | 12.28% | 13.98% |
| Sharpe ratio | 0.22 | 1.66 |
| Sortino ratio | 0.30 | 2.38 |
| Maximum drawdown | −24.5% (28-02-2025) | −14.9% (28-02-2025) |
| Beta | 0.87 | 0.95 |
| Alpha | −2.91% | +8.51% |
From daily NAVs, 09-03-2023 to 30-10-2026. Standard deviation: how much the daily value swings, scaled to a year. Sharpe: return above the risk-free rate (NSE's overnight rate index) per unit of swing. Sortino: the same, counting only the falls. Beta and alpha compare each fund with its own benchmark's TRI.
Drawdowns
How far below its previous high each one was on every day: the falls an investor had to sit through. 0% means it was at a new high.
HDFC MNC Fund (Direct)
HDFC Pharma and Healthcare Fund (Direct)
Nifty MNC TRI
| Fund | Worst fall | High before it | Bottom | Back at the high | Time to climb back | Below its high today |
|---|---|---|---|---|---|---|
| HDFC MNC Fund (Direct) | −24.5% | 01-10-2024 | 28-02-2025 | Not yet | -- | −13.0% |
| HDFC Pharma and Healthcare Fund (Direct) | −14.9% | 02-01-2025 | 28-02-2025 | 04-07-2025 | 4 months | −4.1% |
| Nifty MNC TRI | −23.5% | 01-10-2024 | 28-02-2025 | 29-04-2026 | 14 months | −16.0% |
From daily values since 04-10-2023, the first day every fund has.
Rolling standard deviation
Whether the swings have grown or calmed over time: the standard deviation of daily changes over every 1-year window, scaled to a year, plotted on the window's last day. Higher means a bumpier ride.
HDFC MNC Fund (Direct)
HDFC Pharma and Healthcare Fund (Direct)
Nifty MNC TRI
Whether the swings have grown or calmed over time: the standard deviation of daily changes over every 3-year window, scaled to a year, plotted on the window's last day. Higher means a bumpier ride.
HDFC MNC Fund (Direct)
HDFC Pharma and Healthcare Fund (Direct)
Nifty MNC TRI
Against Nifty MNC TRI
| Fund | Up capture | Down capture | Tracking error |
|---|---|---|---|
| HDFC MNC Fund (Direct) | 82% | 95% | 6.10% |
| HDFC Pharma and Healthcare Fund (Direct) | 104% | 15% | 16.53% |
From month-end values since 04-10-2023. Up capture: a fund's average month when the benchmark rose, as % of the benchmark's; above 100% it gained more. Down capture: the same for months the benchmark fell; below 100% it fell less. Tracking error: how far the monthly returns strayed from the benchmark's, a year; an index fund aims near 0.
HDFC MNC vs HDFC Pharma and Healthcare: Portfolio Overlap
From each fund's latest monthly portfolio: HDFC MNC Fund, September 2026; HDFC Pharma and Healthcare Fund, September 2026
Holdings in common
- Overlap
- 19.7%
- Held by both
- 12
- Only in HDFC MNC
- 31
- Only in HDFC Pharma and Healthcare
- 26
| Security | % of HDFC MNC | % of HDFC Pharma and Healthcare |
|---|---|---|
| Torrent Pharmaceuticals Ltd. | 3.86% | 3.65% |
| Neuland Laboratories Limited | 3.02% | 3.24% |
| Divis Laboratories Ltd. | 2.58% | 9.39% |
| Sun Pharmaceutical Industries Ltd. | 2.47% | 8.28% |
| Gland Pharma Ltd. | 3.03% | 1.78% |
| Ipca Laboratories Ltd. | 1.33% | 2.98% |
| Rubicon Research Limited | 1.18% | 2.52% |
| SYMBIOTEC PHARMALAB LIMITED | 1.11% | 1.36% |
| Molbio Diagnostics Limited | 0.97% | 2.01% |
| Lupin Ltd. | 0.64% | 3.55% |
| Wockhardt Ltd. | 0.56% | 1.71% |
| Novartis India Ltd. | 0.44% | 0.55% |
Overlap: for each holding both funds own, the smaller of its two weights, added up. 19.7% means 19.7% of each fund's money sits in positions the other also holds. Matched by ISIN. Cash and hedged positions are left out.
Largest holdings only in HDFC MNC Fund
| Security | % of fund |
|---|---|
| Maruti Suzuki India Limited | 8.14% |
| Britannia Industries Ltd. | 5.81% |
| Hindustan Unilever Ltd. | 5.53% |
| Cummins India Ltd. | 4.58% |
| Nestle India Ltd. | 4.44% |
Largest holdings only in HDFC Pharma and Healthcare Fund
| Security | % of fund |
|---|---|
| Alkem Laboratories Ltd. | 4.64% |
| Cipla Ltd. | 4.15% |
| Apollo Hospitals Enterprise Ltd. | 3.69% |
| Max Healthcare Institute Limited | 3.61% |
| Aster DM Quality Care Limited | 3.56% |
Asset and sector split
Share of each fund, from its latest monthly portfolio
Asset allocation
| Asset | HDFC MNC | HDFC Pharma and Healthcare |
|---|---|---|
| Equity | 96.2% | 96.8% |
| Debt | 0.0% | 0.0% |
| Cash and others | 3.8% | 3.2% |
Market cap of stocks
| Market cap | HDFC MNC | HDFC Pharma and Healthcare |
|---|---|---|
| Large Cap | 51.4% | 29.2% |
| Mid Cap | 24.0% | 30.1% |
| Small Cap | 17.4% | 32.5% |
| Not on AMFI's list | 3.3% | 5.0% |
Share of the whole fund. Groups follow AMFI's latest list: Large Cap is the 100 largest companies, Mid Cap the next 150, Small Cap the rest.
Largest sectors
| Sector | HDFC MNC | HDFC Pharma and Healthcare |
|---|---|---|
| Pharmaceuticals & Biotechnology | 20.2% | 71.3% |
| Healthcare Services | 0.0% | 22.1% |
| Automobiles | 11.0% | 0.0% |
| Food Products | 10.3% | 0.0% |
| Industrial Products | 9.0% | 0.0% |
| Auto Components | 8.1% | 0.0% |
| Electrical Equipment | 7.5% | 0.0% |
| Healthcare Equipment & Supplies | 1.0% | 2.4% |
| Retailing | 0.0% | 1.0% |
The six largest sectors of each fund's stocks, % of the fund.
HDFC MNC vs HDFC Pharma and Healthcare: Expense Ratio
What each plan charges a year, from AMFI's expense ratio file
| Charge | HDFC MNC Fund | HDFC Pharma and Healthcare Fund |
|---|---|---|
| Total expense ratio (Direct) | 1.86% | 1.05% |
| Base expense ratio (Direct) | 1.20% | 0.71% |
| Total expense ratio (Regular) | 2.89% | 2.13% |
| Base expense ratio (Regular) | 2.10% | 1.65% |
The expense ratio comes out of the fund's assets every day, so every return on this page is already after it. Base expense ratio: the fund house's own fee. The total adds brokerage, transaction costs, and levies with GST.
More comparisons
Each fund against the others of its category
Compare HDFC MNC with
HDFC MNC Fund vs HDFC Pharma and Healthcare Fund: Frequently Asked Questions
What is the difference between HDFC MNC Fund and HDFC Pharma and Healthcare Fund?
HDFC MNC Fund is a Thematic fund, HDFC Pharma and Healthcare Fund is a Thematic fund, run by HDFC Mutual Fund. Their portfolios overlap 19.7%. HDFC MNC Fund charges 1.86% a year and HDFC Pharma and Healthcare Fund 1.05%.
Which has given higher returns, HDFC MNC Fund or HDFC Pharma and Healthcare Fund?
Over 1 year: HDFC MNC Fund −3.66%, HDFC Pharma and Healthcare Fund +23.12%. Over 3 years: HDFC MNC Fund +6.19% a year, HDFC Pharma and Healthcare Fund +30.53% a year. As on 30-10-2026. Past returns do not promise future returns.
Which has the lower expense ratio, HDFC MNC Fund or HDFC Pharma and Healthcare Fund?
HDFC Pharma and Healthcare Fund charges less: 1.05% a year against 1.86%. These are the Direct plans' total expense ratios reported to AMFI.
How much do HDFC MNC Fund and HDFC Pharma and Healthcare Fund overlap?
19.7%. They hold 12 of the same securities, the largest shared ones being TORNTPHARM, NEULANDLAB, DIVISLAB. From each fund's latest monthly portfolio.
Which is riskier, HDFC MNC Fund or HDFC Pharma and Healthcare Fund?
On SEBI's riskometer, HDFC MNC Fund is rated Very High and HDFC Pharma and Healthcare Fund Very High. Over 3 years, the standard deviation of daily returns was 13.13% and 14.09% a year.
Which is better for SIP, HDFC MNC Fund or HDFC Pharma and Healthcare Fund?
Over the last 3 years, a monthly SIP of ₹10,000 from 03-10-2023 to 30-10-2026 grew to ₹3,74,818 in HDFC MNC Fund (XIRR 0.8% a year) and ₹5,26,145 in HDFC Pharma and Healthcare Fund (XIRR 23.6% a year). Both received 37 instalments. Past returns do not promise future returns.
Can I invest in both HDFC MNC Fund and HDFC Pharma and Healthcare Fund?
Yes. 19.7% of each fund's money sits in the same holdings, so some of the two investments would move together.
Who manages HDFC MNC Fund and HDFC Pharma and Healthcare Fund?
HDFC MNC Fund: Amar Kalkundrikar, Gopal Agrawal, Bhagyesh Kagalkar. HDFC Pharma and Healthcare Fund: Nikhil Mathur, Gopal Agrawal, Bhagyesh Kagalkar.
Sources: NAV and expense ratio from AMFI. Holdings from each fund house's monthly portfolio statement. Fund facts from each scheme summary document.
This page is information, not investment advice. Mutual fund investments are subject to market risks; read all scheme related documents carefully. Past returns do not promise future returns. Figures come from AMFI, NSE, BSE and each fund house's own documents.